Citas bibligráficas
Paredes, C., (2023). Eficacia de las vacunas contra el dengue en América Latina: revisión sistemática y metaanálisis [Tesis, Universidad Privada Antenor Orrego]. https://hdl.handle.net/20.500.12759/15751
Paredes, C., Eficacia de las vacunas contra el dengue en América Latina: revisión sistemática y metaanálisis [Tesis]. PE: Universidad Privada Antenor Orrego; 2023. https://hdl.handle.net/20.500.12759/15751
@misc{renati/372607,
title = "Eficacia de las vacunas contra el dengue en América Latina: revisión sistemática y metaanálisis",
author = "Paredes Vargas, Carlos Fernando",
publisher = "Universidad Privada Antenor Orrego",
year = "2023"
}
This study aimed to compile the different scientific evidence that allows determining the effectiveness of vaccination against dengue in patients in Latin America. Material and methods: The search was carried out in Pubmed, Scopus, Web of Science, Cochrane and gray literature for original articles that report the variables of interest that evaluate the effectiveness of the dengue vaccine in any of its presentations, on the Latin American population. Studies were independently assessed and selected by investigators, exposed data were extracted for associations of interest and processed using Revman 5.4 software. Results: A total of 1499 articles were obtained, 355 duplicate articles were eliminated, resulting in 1144 articles in total that were reviewed by titles and abstract, excluding 1071 articles that did not meet the selection criteria. The resulting 73 articles were reviewed in full text and only 5 clinical trials met the selection criteria for this review. The analysis included a total population of 41,984 people, aged between 2 and 16 years. The combined RR was 0.36 (95% CI 0.31 – 0.40 p <0.05), suggesting a protective effect of the vaccine on the control group, with a statistically significant effect. Conclusions: The estimated efficacy of the vaccine is 64% with a range of 60% to 69%. No major adverse effects were recorded, however, the application of vaccines on the seronegative population is essential to determine more solid efficacy.
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons